Pathfinder supporter Heather Rangel held a special fundraising event for Cancer Commons on Monday. The party celebrated the life of her good friend Jackie Tran, who recently passed from ovarian cancer. In Jackie’s honor, Heather brought together her friends and family to raise funds for Cancer Commons. The night opened with poignant words from Heather and Cancer Commons founder Marty Tenenbaum, as well as an uplifting video that encouraged gratitude. A performance by the band Rusted Root drew guests to the dance floor for a joyful celebration.
Come support Cancer Commons and celebrate the life of Jackie Tran, a close friend of our Pathfinder donor Heather Rangel. The event features the band Rusted Root, and will take place at the Fox Forum in Redwood City, CA, on Monday, November 3 at 7 PM. Please feel free to invite your friends and family. Every dollar raised will go towards creating the world’s most valuable resource for cancer patients. Click here to purchase your ticket(s).
Cancer Commons aims to put the most up-to-date information about cancer treatment into the hands of patients. To keep this information current, Cancer Commons’ Chief Scientist Emma Shtivelman and collaborators periodically comb the scientific literature to compile and publish review papers that serve as “consensus models” of different cancer types and how they’re treated. A new consensus model was recently published for prostate cancer in the scientific journal Oncotarget.
The new consensus model describes the molecular underpinnings of prostate cancer, and how different genetic mutations and other molecular-scale changes are used to develop different treatments. The model serves as the scientific foundation of the personalized, patient-friendly information Cancer Commons provides to prostate cancer patients, and it will be updated as new insights emerge.
Cancer Commons founder Marty Tenenbaum, PhD, will be speaking at a special MIT Club of Northern California event in Mountain View, CA, on September 23. From the event registration page:
“Every year 1.6 million Americans are diagnosed with cancer and nearly half of those cases are considered incurable. But many of those ‘incurable’ cases may be beatable by exploiting biological features unique to each individual’s cancer. I will talk about a convergence of recent developments in genomics, big data informatics, social networks, and personalized medicine that is transforming the landscape of cancer research and treatment. Instead of aiming our efforts toward curing ‘cancer’ in the abstract, and often failing, we are now on the threshold of being able to give each individual the knowledge, resources, and tools needed to successfully treat the one disease that matters most to them.”
The event is open to the public. Visit the registration page for details and pricing.
New personalized medicine publication Genome features Cancer Commons in its latest issue. The article highlights Cancer Commons’ mission, with supporting remarks from Founder Marty Tenenbaum, PhD, and Executive Director William Wong, PhD.
From the article:
“[Cancer Commons is] the very model of personalized medicine, a way for cancer patients to have their unique challenges analyzed against the largest data set possible and be shown the most relevant data to their individual case. This is important for patients who often feel like they are adrift once they’re diagnosed, Tenenbaum says.”
Shortly after her mother was diagnosed with breast cancer in early 2013, Stacey Tinianov went in for her first mammogram. Several days and one biopsy later, she got a phone call that said she, too, had breast cancer.
“I went from my very first mammogram to, ‘you need to have a mastectomy,’ in two weeks,” Stacey said. “And what I was missing were options. I was missing options with context.” Continue reading…
Earlier this year, Cancer Commons founder Marty Tenenbaum, PhD, spoke at the Bonnie J. Addario Lung Cancer Foundation’s (ALCF) monthly Lung Cancer Living Room event. Marty’s own cancer diagnosis and treatment journey inspired his current mission: to make sure critical information is shared and gets to the patients who need it. By collecting data from thousands of patient-donated lung cancer stories, Cancer Commons can begin to show patients and doctors patterns in treatment choices, side effects, quality of life, outcomes, and more.
The ALCF, one of our partner organizations, works directly with individual lung cancer patients to ensure they each receive the best possible care. The Lung Cancer Living Room is a monthly in-person and online support group event that informs patients about lung cancer.
Click here for more information, including how to attend in person (in San Carlos, CA) or online. Click here to read the description of Marty’s upcoming event.
On June 10, 2014, Cancer Commons held the inaugural event in its new Pathfinders Conversation Series (PCS). The Conversation brought together researchers, physicians, patients, the Cancer Commons team, and The Pathfinders (Cancer Commons’ donors) for an evening in Palo Alto, CA, to discuss some of the biggest challenges in cancer research today. Several guests who had personally dealt with cancer opened with their poignant stories, and the event progressed into a discussion of how existing data and information could be captured, analyzed, and shared more efficiently, for the benefit of all cancer patients.
“Information is the biggest deficit and really the lowest hanging fruit to changing the whole world of cancer,” said John Adler, MD, Professor Emeritus of Neurosurgery at Stanford University and Founder of Cureus. “As a community of physicians and patients, we need to take charge of our medical information and create something bigger than we can as individuals.”
Cancer Commons aims to put the most up-to-date information about cancer treatment into the hands of patients. To keep this information current, Cancer Commons’ Chief Scientist Emma Shtivelman and collaborators periodically comb the scientific literature to compile and publish review papers that serve as “consensus models” of different cancer types and how they’re treated. Two new consensus models were recently published for lung cancer and melanoma in the scientific journal Oncotarget.
The new consensus models describe the molecular underpinnings of lung cancer and melanoma, and how different genetic mutations and other molecular-scale changes are used to develop different treatments. The models serve as the scientific foundation of the personalized, patient-friendly information Cancer Commons provides to lung cancer and melanoma patients, and they will be updated as new insights emerge.
Cancer Commons is also preparing a prostate cancer consensus model for publication. Consensus models for other cancer types may be published as we expand our services.
Both models are available free of charge on the Oncotarget website: